MAP4K1 and metastatic malignant neoplasm: Collectively, these results highlighted HPK1 in NK cells as a candidate target for treating metastatic cancer and its cooperative therapeutic combination with anti‐PD‐1 and anti‐CTLA‐4 therapy.